G-Spot Amplification ("G-Shot")
G-spot amplification — the "G-shot" — is a cosmetic procedure that injects a dermal filler (typically hyaluronic acid), collagen, or autologous fat into the anterior vaginal wall at the putative Gräfenberg spot, with the goal of enhancing sexual pleasure and orgasm. It is among the most controversial female genital cosmetic procedures: the anatomical existence of the G-spot as a discrete structure is itself scientifically debated, no RCTs of G-spot amplification specifically exist, and both ACOG 2020 and FIGO 2025 consider the procedure not medically indicated, with safety and effectiveness not established.[1][2][3] For positioning vs other female cosmetic options see Cosmetic Genital Surgery — Female.
- Anatomy. A literature review concluded that all published scientific data point to the fact that the G-spot does not exist as a distinct anatomical entity; the concept has been conflated with the broader clitoral-urethral-vaginal complex.[1]
- ACOG 2020 Committee Opinion No. 795 — G-spot amplification is not medically indicated, poses substantial risk, and safety / effectiveness have not been established. Evidence is restricted to expert opinion, case reports, and small case series.[2]
- FIGO 2025 Statement — it is ethically inappropriate for obstetrician-gynecologists to recommend, perform, or refer patients for cosmetic genital procedures in women without structural or functional abnormalities.[3]
- Mandatory BDD screening belongs at the front of every consultation.
Background — the G-spot controversy
In 1950, Ernst Gräfenberg described a distinct erotogenic zone on the anterior vaginal wall. The term "G-spot" was coined by Addiego, Whipple et al. in 1981.[1] Since then, attempts to confirm a discrete G-spot anatomically have been unsuccessful; contemporary models frame the responsive area as part of the broader clitoral-urethral-vaginal complex rather than a discrete structure.[1][4] Despite this, the concept has driven significant commercial interest and the development of G-spot amplification procedures.[1][4]
Procedure
G-spot amplification is a minimally invasive, office-based procedure depositing an injectable substance into the bladder–vaginal septum (anterior vaginal wall), approximately 2–3 cm inside the introitus, at the area believed to correspond to the G-spot.[1][2]
Injectable agents
| Agent | Description | Duration |
|---|---|---|
| Hyaluronic acid (HA) dermal filler | Most commonly used. Cross-linked HA provides temporary volume augmentation. | ~ 9–12 months[5] |
| Collagen-based filler | Earlier formulations (human-derived collagen) | 3–4 months[1] |
| Autologous fat (microfat / MAFT) | Harvested via liposuction; provides volume + potential regenerative effects via ADSCs | Variable (subject to fat-graft survival); stable at 18 months in one series[6][7] |
Technique — HA injection
- Anesthesia. Local (topical or infiltrative).
- Injection. Submucosal deposition into the anterior-vaginal-wall target area; typical volumes 1–5 mL depending on agent and technique.[5]
- Procedure time. ~ 15–30 min as an outpatient procedure.
Technique — autologous fat injection
- Fat harvested from abdomen / thighs / flanks via liposuction; processed (washed, filtered, or centrifuged) into microfat or nanofat; injected into the vaginal wall.
- Lai 2023 MAFT series injected an average of 21.9 mL into the vagina.[6]
- More involved than HA injection — requires a donor-site procedure.
Proposed mechanism of action
The theoretical rationale is that increasing volume and turgor of anterior vaginal wall tissue at the G-spot area would[1][6]:
- Increase mechanical pressure on underlying nerve-rich tissue during intercourse.
- Enhance sensitivity and arousal.
- Facilitate vaginal orgasm.
For autologous fat, additional proposed mechanisms include tissue regeneration through ADSCs, with histologic evidence of neocollagenesis, neoangiogenesis, and increased estrogen-receptor expression in vaginal tissue after fat grafting (Lai 2023).[6]
Evidence — extremely limited for G-spot amplification specifically
The evidence base for G-spot amplification specifically is extremely limited. ACOG: "scant information on the outcomes (risks and benefits) of G-spot amplification exists in the peer-reviewed literature, and the published data are mostly restricted to expert opinion, case reports, or small case series."[2]
Adjacent vaginal-augmentation evidence (NOT G-spot-specific)
| Study | Agent | n | Follow-up | Key outcomes |
|---|---|---|---|---|
| Yi 2026[5] | Cross-linked HA (posterior vaginal wall) | 42 | 12 mo | All FSFI domains improved; 81% satisfaction; improved Peritron parameters |
| Lai 2023[6] | Autologous fat (MAFT, vulvovaginal) | 20 | 6 mo | FSFI 43.8 → 68.6 (p < 0.001); histologic neocollagenesis + neoangiogenesis |
| Menkes 2021[7] | Microfat + nanofat (vulvovaginal) | 50 | 18 mo | VHI + FSD significantly improved; 80% normalized at 6 mo; stable at 18 mo |
| Clarke 2026 RCT[8] | PRP (anterior vaginal wall) vs saline | 52 | 6 mo | Greater FSFI improvement with PRP vs saline at 6 wk (2.2 vs 0.3); 69.2% vs 34.6% reported improvement at 6 mo (p = 0.01) |
| Bensmail 2025[9] | Cross-linked HA (vulvovaginal, postmenopausal) | 115 | 52 wk | Significant reduction in VVA symptoms + FSFI improvement maintained to 52 wk |
Most of these studies address vaginal augmentation broadly — for laxity, atrophy, or genitourinary syndrome of menopause — rather than G-spot amplification specifically. The Clarke 2026 anterior-vaginal-wall PRP RCT is the closest available proxy and showed greater improvement in sexual function vs saline, though individual FSFI subscale differences did not reach statistical significance.[8]
Duration of effect
| Agent | Typical duration |
|---|---|
| HA fillers | ~ 9–12 mo before reabsorption; repeat injections to maintain[5] |
| Autologous fat | Variable graft survival; results stable at 18 mo in one series[7] |
| Collagen | 3–4 mo[1] |
Complications
ACOG-listed complications for G-spot amplification and related cosmetic genital procedures[2]:
| Complication | Notes |
|---|---|
| Pain | Generally minimal with HA; donor-site discomfort with fat |
| Bleeding | Submucosal hematoma rare |
| Infection | Rare |
| Scarring / adhesions | Rare |
| Altered sensation | Hyper- or hyposensitivity reported |
| Dyspareunia | Possible — especially over-correction |
| Filler migration / granuloma | Theoretical with HA; not specifically reported in vaginal G-spot use |
| Donor-site morbidity | Autologous fat technique only |
| Need for reoperation | Re-injection commonly required to maintain effect |
No serious adverse events were reported in the small published vaginal HA / fat-injection series, but small samples and short follow-up limit detection of rare complications.[5][6][7]
Distinction — cosmetic G-spot amplification vs therapeutic vaginal augmentation
A clinically important distinction:
| Use case | Status | Evidence |
|---|---|---|
| G-spot amplification for sexual enhancement in healthy women | Cosmetic; not medically indicated; lacks evidence | Expert opinion / case reports / small series only[1][2] |
| Vaginal HA / fat injection for genitourinary syndrome of menopause (GSM) | Emerging therapeutic application | Bensmail 2025 placebo-controlled RCT (HA; 52-wk benefit); Menkes 2021 microfat / nanofat at 18 mo[9][7][10] |
The therapeutic application has a stronger and more clinically grounded evidence base. Counseling must distinguish these contexts clearly — patients seeking G-spot amplification for sexual enhancement are not the same population as patients with GSM, and the evidence base for the former does not transfer to the latter.
Emerging techniques
| Technique | Description | Reference |
|---|---|---|
| Cannulated Intravaginal Injection Technique (CIVIT) | Cannula-based HA delivery for more homogeneous, less traumatic distribution; superior to random needling on FSFI / GU symptoms in one series | Leylek 2025[11] |
| Anterior-vaginal-wall PRP | First RCT of vaginal PRP injection — significant FSFI improvement vs saline at 6 mo (69.2% vs 34.6%, p = 0.01) | Clarke 2026[8] |
| Microfragmented adipose tissue | Minimally processed adipose tissue injection for GSM — improvement at 5 mo in a small cohort | Mantovani 2022[10] |
Key takeaways
- No RCTs specifically for G-spot amplification.[2]
- The anatomical existence of the G-spot as a discrete structure is debated; contemporary models frame the responsive area as part of the broader clitoral-urethral-vaginal complex.[1]
- ACOG 2020 + FIGO 2025: G-spot amplification is not medically indicated; clinicians should not recommend or perform it in women without structural / functional abnormalities.[2][3]
- The broader vaginal-augmentation literature (HA / fat / PRP for GSM and vulvovaginal atrophy) is generating better RCT data — but those data do not transfer to the cosmetic G-shot context. Counsel accordingly.
- The procedure has a temporary effect and requires repeat injections; patients should be informed of cost and durability limits.
Postoperative management
- Activity restriction. Avoid intercourse, tampon use, and strenuous exercise for 1–2 weeks after HA injection; longer (4 weeks+) after autologous fat to protect graft survival.
- Wound care. Generally not required after HA injection; sitz baths / loose clothing if discomfort.
- Donor-site care for autologous fat — compression, ice, monitor for hematoma.
- Follow-up. Initial check at 2 weeks; functional / satisfaction assessment at 3 and 6 months. Counsel that effect will wane — re-injection schedule depends on agent.
See Also
- Female Cosmetic Genital Surgery (umbrella)
- Labia Majora Augmentation (Autologous Fat Grafting) — the volume-augmentation analogue with stronger evidence
- Fat Grafting to Mons Pubis
- Vaginal Laser Therapy — the canonical cross-indication page for energy-based vulvovaginal therapies (GSM / SUI / lichen sclerosus / vaginal laxity / breast-cancer survivors)
References
1. Puppo V, Gruenwald I. Does the G-spot exist? A review of the current literature. Int Urogynecol J. 2012;23(12):1665–1669. doi:10.1007/s00192-012-1831-y
2. Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery: ACOG Committee Opinion No. 795. Obstet Gynecol. 2020;135(1):e36–e42. doi:10.1097/AOG.0000000000003616
3. Capito L, Antsaklis A, Gupte S. FIGO Statement: cosmetic genital surgery. Int J Gynaecol Obstet. 2025;170(1):11–14. doi:10.1002/ijgo.70203
4. Wilkie G, Bartz D. Vaginal rejuvenation: a review of female genital cosmetic surgery. Obstet Gynecol Surv. 2018;73(5):287–292. doi:10.1097/OGX.0000000000000559
5. Yi KH, Kim JH, Rosellini I, et al. Hyaluronic acid fillers for vaginal augmentation: efficacy and safety. Aesthet Plast Surg. 2026;50(7):2626–2632. doi:10.1007/s00266-025-05587-0
6. Lai YW, Wu SH, Chou PR, et al. Autologous fat grafting in female genital area improves sexual function by increasing collagenesis, angiogenesis, and estrogen receptors. Aesthet Surg J. 2023;43(8):872–884. doi:10.1093/asj/sjad040
7. Menkes S, SidAhmed-Mezi M, Meningaud JP, et al. Microfat and nanofat grafting in genital rejuvenation. Aesthet Surg J. 2021;41(9):1060–1067. doi:10.1093/asj/sjaa118
8. Clarke B, Gaddam N, Garcia B, et al. Vaginal injection of platelet-rich plasma for sexual function: a randomized controlled trial. Obstet Gynecol. 2026;147(5):627–635. doi:10.1097/AOG.0000000000006256
9. Bensmail H, Marchand Lamiraud F, Martin C, et al. Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy and improve sexual function in postmenopausal women: a 52-week long-term follow-up. Maturitas. 2025;201:108687. doi:10.1016/j.maturitas.2025.108687
10. Mantovani M, Gennai A, Russo PR. A new approach to regenerative medicine in gynecology. Int J Gynaecol Obstet. 2022;157(3):536–543. doi:10.1002/ijgo.13906
11. Leylek O, Peker BH, Demircivi E, Peker H. Cannulated intravaginal injection technique (CIVIT) — a novel vaginal injection technique. Sci Rep. 2025;15(1):7651. doi:10.1038/s41598-025-91069-x